Repros Therapeutics Inc. (RPRX.W)

RPRX.W on CBOE When Trading NASDAQ Global Select Market

0.83USD
9 Feb 2010
Price Change (% chg)

$-0.02 (-2.35%)
Prev Close
$0.85
Open
$0.83
Day's High
$0.83
Day's Low
$0.83
Volume
200
Avg. Vol
4,276,028
52-wk High
$10.60
52-wk Low
$0.64

RPRX.W

Chart for RPRX.W

About

Repros Therapeutics Inc. (RPRX) is a development-stage biopharmaceutical company focused on the development of oral small molecule drugs for unmet medical needs. The Company's principal drug, Proellex, is a selective blocker of the progesterone receptor and is being developed for the treatment of uterine fibroids, anemia... (more)

Overall

Beta: -0.00
Market Cap (Mil.): $20.94
Shares Outstanding (Mil.): 25.54
Annual Dividend: 0.00
Yield (%): NA

Financials

  RPRX.W Industry Sector
P/E (TTM): -- 11.50 3.76
EPS (TTM): -17.20 -- --
ROI: -- 1.25 2.30
ROE: -- 2.09 2.82
view overview for:

UPDATE 3-Repros gets FDA advice on testosterone drug, shrs soar

* FDA asks to propose a label to define patient population

27 Jan 2010

UPDATE 1-Repros posts wider-than-expected Q3 loss

Nov 9 (Reuters) - Cash-strapped Repros Therapeutics Inc reported a wider-than-expected quarterly loss, sending its shares down about 25 percent in pre-market trade.

09 Nov 2009

UPDATE 1-Repros amends agreement over Proellex license

NEW YORK, Oct 28 (Reuters) - Repros Therapeutics Inc signed an amendment with the National Institutes of Health (NIH) to its license for Proellex, the company's experimental drug for uterine fibroids on hold for safety reasons.

28 Oct 2009

UPDATE 1-Repros, Targacept to offer shares at discount

Oct 8 (Reuters) - Shares of Repros Therapeutics Inc and Targacept Inc fell sharply, after the companies said they plan to raise money by selling shares at a discount.

08 Oct 2009

UPDATE 1-Repros' testosterone drug shows promise, shares soar

(Adds analyst comment, details; updates share movement)

07 Oct 2009

Repros' testosterone drug successful in small study, shares soar

Oct 7 (Reuters) - Repros Therapeutics Inc said its experimental drug Androxal restored normal sperm count while increasing testosterone levels in an exploratory study, sending its shares up nearly three-fold.

07 Oct 2009

Repros shares down, FDA asks for more data

NEW YORK (Reuters) - Shares of Repros Therapeutics fell 19 percent to 88 cents in premarket trading on Tuesday, after the company said the Food and Drug Administration asked for additional data on the company's lead drug Proellex to resolve the clinical hold placed on it.

29 Sep 2009

UPDATE 1-Repros says FDA asks for more data on lead drug

* Says new development requirements beyond its abilities

29 Sep 2009

HEADLINE STOCKS-Some U.S. stocks on the move on Aug 17

(Updates to afternoon trading, adds Atlas Pipeline and Align/Danaher)

17 Aug 2009

UPDATE 2-Repros Therapeutics runs out of cash, may go bankrupt

* Says doesn't have enough cash to fund ongoing operations

17 Aug 2009

  Earnings  vs    Estimates

view overview for: